Post Marketing Surveillance(PMS) Study of Lorviqua in Korea

NCT05599412

Status	RECRUITING
Sponsor	Pfizer
Enrollment	600 participants

Plain Language Summary

This post-market surveillance study monitors real-world use of lorlatinib (brand name Lorviqua) in adult patients with a specific type of advanced lung cancer in South Korea. The study collects safety and effectiveness data as the drug is used in routine clinical practice.

You may be eligible if...
- You are an adult being treated with lorlatinib for ALK-positive metastatic non-small cell lung cancer (NSCLC)
- You have provided written informed consent

You may NOT be eligible if...
- You are not being treated with lorlatinib as part of your standard care
- You do not have the ALK gene mutation in your lung cancer
- You are under 18 years old

Talk to your doctor to see if this trial is right for you.

Key Eligibility Criteria

Inclusion (2)

- Use in the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC)
- Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.

Exclusion (3)

- Patients meeting any of the following criteria will not be included in the study:
- Patients to whom Lorviqua® is contraindicated as per the local labeling. A. Hypersensitivity to Lorviqua® or to any of the excipients of this product B. Lorviqua® is contraindicated in patients taking concomitant use of strong CYP3A4/5 inducers C. This medicinal product contains lactose as an excipient. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose galactose malabsorption should not take this medicinal product.
- Any patients (or a legally acceptable representative) who does not agree that Pfizer and companies working with Pfizer use his/her information

Locations (1 total)

Pfizer, Seoul, South Korea